Sorry for interrupting, but there is something we need to tell you...

We have updated our Cookie Policy to reflect changes in the law on cookies used on websites in Europe. This website uses cookies to maximize your experience and help us to understand how we can improve it. To find out more click here.

Cookies are text files containing small amounts of data which are downloaded to your computer, or other device, when you visit a website. Cookies allow us to recognize your computer and improve your experience on our website. Some cookies are also necessary for the technical operation of our website. Please read our Cookie Policy which provides important information about the cookies we use, how we use them and how they can be deleted. Please remember that deleting cookies may affect your experience of our website.

Show less.

Accept and hide this message
Pillsbury Pillsbury Pillsbury
San Francisco
Four Embarcadero Center
22nd Floor
San Francisco, CA 94111-5998
Tel. +1.415.983.1077
Fax. +1.415.983.1200
State of California
J.D., Harvard Law School, 1974
cum laude
B.A., Yale University, 1971
magna cum laude


Kirke M. Hasson

Kirke M. Hasson

Kirke Hasson is leader of the law firm's Trials team and co-leader of the firm's Litigation practice. His practice includes a range of litigation, including corporate and committee investigations; disputes in the technology and life sciences fields related to intellectual property rights, licensing and collaborative agreements, and patents; fiduciary liabilities; mergers and acquisitions disputes; shareholder and securities claims; and appeals. In these areas, Mr. Hasson has prosecuted and defended numerous state and federal trial court and arbitration cases and appeals as lead counsel.

Representative Matters
Collaboration, License and Related Contract Disputes
  • Representation of selling stockholders of a drug development company in collection of milestones from purchaser related to regulatory progress of drug
  • Representation of Affymax, Inc. in resolution of dispute with Johnson & Johnson regarding rights arising from collaboration agreement and related patents
  • Representation of Arriva Pharmaceuticals and its principals in defense of claim of fiduciary breach by certain shareholders
  • XOMA Ltd. v. Biosite Incorporated (U.S. District Court , N.D. Cal.) - Action regarding purported termination of license to patents regarding modular assembly of antibodies
  • Immunex Corporation and Amgen Inc. v. Trustees of Columbia University and related action (U.S. District Courts, C.D. Cal. and D. Mass. (MDL case) - Action regarding rights under license to Axel patents regarding cotransformation of mammalian cells to produce proteins of interest
  • Elan Pharmaceuticals v. Eli Lilly (U.S. District Court, N.D. Cal.) - Action establishing rights of ownership to vaccine for Alzheimer’s disease
  • Immune Response Corporation v. Rhone-Poulenc Rorer (AAA arbitration, Chicago) - Arbitration establishing rights of ownership and control of Jonas Salk’s AIDS vaccine
  • Regents of the University of California v. Agouron Pharmaceuticals, Inc. (later, Pfizer Inc) (California Superior Court) - Action to resolve dispute regarding royalty base under license agreement regarding material used to make protease inhibitor
  • Artes Medical USA, Inc. v. BioForm Medical, Inc. (U.S. District Court, S.D. Cal.; California Superior Court; Regional Court, Patent Panel, Frankfurt, Germany) - Actions to determine rights under option and license agreement for patent regarding medical device implant materials
  • Rehabilitation Technologies, Inc. v. Smith Laboratories (California Superior Court and Court of Appeal) - Action challenging failure to close on sale of medical device company
  • Confidential ICC Arbitration between major pharmaceutical companies - Action to determine ownership, trade secrets and enforcement rights regarding biotechnology materials and related patents
  • Confidential AAA Arbitration for major medical device manufacturer - Action to determine royalty base for license relating to cardiac medical device technology


  • Representation of Audit Committee of public holding company regarding significant restatement in financial services industry
  • Representation of Special Committees and Audit Committees of public companies regarding restatement investigations relating to stock option grants, including restatements up to $1 billion
  • Representation of Special Committee of public company related to restatement related to several accounting issues

Securities Actions
  • Campagnuolo v. IDEC Pharmaceuticals (U.S. District Court, S.D. Cal.) - Action challenging merger of IDEC Pharmaceuticals and Biogen
  • Klein v. Salvi (S.D.N.Y.) - Defense of section 16(b) case relating to pharmaceutical company acquisition of biotech company in Eastern Europe
  • Equity-Linked Investors v. Adams (Delaware Chancery Court) - Action challenging actions of directors of Genta regarding stock offering said to undervalue corporate assets regarding biotechnology company active in antisense field


Actions Regarding Pricing, Consumer Rights, Etc.
  • County of Santa Clara v. Astra et al. (U.S.District Court, N.D.Cal.; Ninth Circuit Court of Appeals; U.S. Supreme Court) – Representation of Schering-Plough Corporation and Merck & Co., Inc. in purported class action challenging alleged industry practices regarding pricing to “Section 340B” qualified entities
  • Representation of former program head of major pharmaceutical company regarding federal investigation of alleged off-label promotion and violation of anti-kickback laws
  • In re Pharmaceutical Industry Average Wholesale Pricing Litigation (Sicor) (U.S. District Courts (several) and MDL in D. Mass.) - Class actions challenging alleged industry practices regarding average wholesale price reporting
  • State of California ex rel. Richardson v. IREF et al. (Sicor) (California Superior Court) - Qui tam action challenging underpayments allegedly made to the University of California by a foundation and pharmaceutical developers
  • Chiron v. SourceCF (U.S. District Court, N.D. Cal.) - Action alleging marketing of unsafe medical device for use in combination with drugs for treatment of CF

Honors & Awards
  • Chambers USA, Life Sciences: IP/IP Patent Litigation—California (2007-2009)
  • Best Lawyers in America, Litigation (2013), Patent Law (2014-2015)
  • PLC Which Lawyer?, Life Sciences: Patent Litigation—National (2011-2012), Life Sciences: Intellectual Property—National (2007-2009)
  • Benchmark Litigation: Guide to America's Leading Firms and Attorneys, Litigation—California (2011-2013)
  • Super Lawyers (2004-2013)

Pillsbury Pillsbury Pillsbury